

Tanezumab

Cat. No.:	HY-P99221
CAS No.:	880266-57-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia ^{[1][2]} .
IC ₅₀ & Target	NGF ^{[1][2]} .

REFERENCES

[1]. Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. *Auton Neurosci*. 2019 May;218:51-53.

[2]. Mantyh P, et al. a humanized anti-nerve growth factor antibody for the treatment of pain[J]. *The Journal of Pain*, 2009, 10(4): S44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA